Detalhe da pesquisa
1.
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Cancer
; 127(8): 1246-1259, 2021 04 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33270904
2.
1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
Bioorg Med Chem Lett
; 22(20): 6460-8, 2012 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-22963766
3.
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.
J Immunol
; 183(1): 696-705, 2009 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19535642
4.
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
Nat Med
; 26(6): 878-885, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32451495
5.
Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation.
Transl Vis Sci Technol
; 6(3): 17, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-28626601
6.
Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Transplantation
; 82(4): 471-8, 2006 Aug 27.
Artigo
Inglês
| MEDLINE | ID: mdl-16926590
7.
Cell signals transduced by complement.
Mol Immunol
; 41(6-7): 583-97, 2004 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-15219997
8.
Profiling tumor counterattack: do Fas ligand-containing microvesicles reduce anticancer immunity?
Clin Cancer Res
; 11(3): 968-70, 2005 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15709161
9.
Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis.
Eur J Immunol
; 35(6): 1939-48, 2005 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-15902683
10.
Fas ligand as a tool for immunosuppression and generation of immune tolerance.
Stem Cells
; 22(6): 908-24, 2004.
Artigo
Inglês
| MEDLINE | ID: mdl-15536183